Choose Dallas Business Journal as a preferred news source to see more of our reporting on Google.

Treatment with omalizumab offers modest protection from allergic reactions to individuals with multiple food allergies, and ...

As clinical research evolves, disruptive trial designs are reshaping how oncology advances. By integrating novel ...

On December 12, Adam Parker, Trivariate Research founder and CEO, appeared on CNBC’s ‘Squawk on the Street’ to talk about his ...

Citing topline data from its Phase 3 TRIUMPH-4, the Indiana-based drugmaker said that retatrutide, a GIP, GLP-1, and glucagon triple hormone receptor agonist, at the two highest doses led to ...

Alpelisib plus fulvestrant significantly improved PFS in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, achieving a median PFS of 7.4 months versus 2.8 months with placebo. The ...

The patchwork rollout of a gene therapy exposes weaknesses in the pricing and regulatory frameworks that determine who ...

FDA Commissioner Marty Makary, North Carolina Governor Josh Stein and Novartis leadership highlight importance of new hub to US patients and ...

Swiss pharmaceutical giant Novartis AG (NYSE:NVS) has entered into a massive $1.7 billion partnership with British ...

DURHAM, N.C. (WTVD) -- Global drugmaker, Novartis, is committed to North Carolina by expanding in three sites in the Research ...

Corporate and political leaders gathered Thursday for a groundbreaking more symbolic than literal. They were celebrating ...

An investment worth $771 million is coming to Research Triangle Park with a massive pharmaceutical company’s expansion.